Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling consequence of neurotoxic therapies, yet factors that modulate the development and clinical impact of CIPN are poorly understood. This epidemiological analysis identifies risk factors for the incidence of CIPN. METHODS: This retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data examined predictors of incident CIPN claims among 11,149 women aged 66 years or older with American Joint Commission on Cancer (AJCC) stage II to IV breast cancer (and no secondary cancer diagnosis or preexisting neuropathy) who received chemotherapy. RESULTS: Overall, new CIPN claims occurred for 8.3% of patients within 1 year of starting chemotherapy. Risk emerged approximately 3 months after the start of chemotherapy and increased throughout 1 year. Paclitaxel as part of first-line therapy increased CIPN risk 2.7-fold in comparison with nonneurotoxic agents (15.9% vs 5.0%), with lower incidence rates for carboplatin and paclitaxel (11.9%), carboplatin and docetaxel (9.3%), carboplatin alone (7.7%), and docetaxel alone (6.6%). The CIPN incidence rate was higher for women who at the time of their breast cancer diagnosis were relatively young (within this Medicare sample), were at AJCC stage II or III, were married or had an equivalent status, and had fewer comorbidities, but it did not differ by race/ethnicity or poverty level. CONCLUSIONS: These Medicare claims database findings indicate that women aged 66 years or older with breast cancer are susceptible to CIPN from taxane and/or platinum compounds, with risk emerging approximately 3 months into treatment. Prospective studies of symptom emergence and clinical response (eg, stopping chemotherapy and adjunctive treatments) are indicated to determine how best to inform patients of this risk and to manage CIPN in this population. 
INTRODUCTION
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of first-line neurotoxic therapeutic agents that undermines cancer survivors' health, function, and quality of life. Literature reviews have estimated the CIPN incidence to vary widely from approximately 10% to 80% of patients according to the cancer type, first-line chemotherapy, treatment dose and duration, comorbidities, and follow-up interval; an exact measure of incidence is complicated by nonstandardized reporting. [1] [2] [3] Recent literature reviews also address the consequences of CIPN, which can limit the chemotherapy dose, interfere with recovery (eg, because of pain, sensory loss, functional impairment, and falls), and lead to a significant health-economic burden. [4] [5] [6] In a recent study, 47% of breast cancer survivors reported experiencing CIPN side effects an average of 6 years after treatment. 7 This study focuses on comparing CIPN occurrence by chemotherapy agents received to explain heterogeneity in CIPN risk among patients with breast cancer. In clinical practice, such agents may be administered alone or in combination and, because of differing mechanisms of action, could conceivably lead to synergistic, additive, offsetting, or null effects on CIPN risk. We currently lack systematic research findings on the incidence of CIPN that could inform clinical decision making. Furthermore, because of the variable estimates in CIPN risks just noted, it is also clinically relevant to consider the severity and broader impact of CIPN. A more conservative baseline estimate may arise from
Cancer January 15, 2019 claims databases, which likely index cases with more severe CIPN with respect to estimates from the clinical literature (which reflect a range of severity). When the risks and benefits of chemotherapy are being balanced, it would be useful for clinicians to have a higher threshold that does not overestimate the risks of, or disability from, CIPN.
As rates of cancer survivorship increase, more patients may experience chronic adverse effects of CIPN unless first-line therapies are developed that lack CIPN as a side effect or adjunctive treatments emerge to treat these side effects. 8 We face many hurdles related to understanding and managing CIPN. For example, the population subgroup prevalence and the time to incidence are not well characterized, 1 the pathophysiology is complex and varies by therapeutic agent, [9] [10] [11] [12] [13] [14] [15] there are no validated biomarkers to predict clinical outcomes, and the lack of Food and Drug Administration-approved medications for treating CIPN currently affords clinicians few safe and effective adjunctive options for managing these problems. 5, [16] [17] [18] There is significant diversity in the use of primary chemotherapeutic agents across cancer types. Thus, analyzing the incidence and progression of CIPN among all patients with cancer creates several challenges, including confounding of the cancer type with the treatment regimen. Patients with breast cancer appear to be at greater risk for CIPN than patients with other cancer types because they are exposed to neurotoxic therapies as part of standard treatment protocols. Furthermore, estimated rates of CIPN may be biased by the ascertainment method (eg, self-report, clinical diagnosis, and claims data), and this may lead to heterogeneity in the severity of CIPN (ie, neuropathy grade). A more stringent criterion, presumably related to greater severity and economic impact and used in the current study, pertains to new claims attributable to CIPN and accounts for comorbidities (eg, diabetes) that could also cause neuropathies. Thus, we focused our initial analysis on women with stage II to IV breast cancer to restrict the sample on cancer type, stage, and sex, and we excluded several other conditions (eg, preexisting neuropathy) and other cancer diagnoses that could potentially confound the analysis while controlling for comorbidities and other sociodemographic factors.
We hypothesized that the incidence of CIPN claims would vary significantly as a function of the neurotoxic agent, American Joint Commission on Cancer (AJCC) stage, and age at diagnosis, and we evaluated risk by race/ ethnicity and income to assess health disparities in the occurrence of CIPN after a breast cancer diagnosis.
MATERIALS AND METHODS
This retrospective cohort study used data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The SEER program is a National Cancer Institute-sponsored program that collects incidence and survival data from 18 population-based cancer registries across the United States representing approximately 28% of the US population. 19 Through a collaborative effort by the SEER program and the Centers for Medicare and Medicaid Services, Medicare enrollment and claims information is linked to SEER clinical, treatment, and outcome data for predominantly older patients (≥65 years) diagnosed with cancer in the United States. 20 The Wayne State University institutional review board reviewed this protocol and determined it to be nonhuman participant research (HPR #2016-104). Figure 1 illustrates study case inclusion and exclusion criteria. Eligible patients were women diagnosed with breast cancer (AJCC stage II-IV) between 2007 and 2013 who received first-line chemotherapy at any point after their diagnosis. Because of the small proportion of women receiving chemotherapy for AJCC stage I disease, data from these women were excluded from the analysis. To assess comorbidities that were present at diagnosis, eligible cases must have been 66 years old or older at the time of diagnosis to allow for the 1 year of prior claims data (ie, starting at the age of 65 years) needed for the comorbidity calculation. We excluded cases with a diagnosis of peripheral neuropathy of any origin (International Classification of Diseases, Ninth Revision [ICD-9] codes 356.0-357.9) before the start of chemotherapy and any case with a second primary cancer (except for nonmelanomatous skin cancer) to ensure that any chemotherapy received could be attributed to the breast cancer diagnosis. Cases must have been enrolled in both Part A and B Medicare and not enrolled in a Medicare health maintenance organization for 12 months before the diagnosis and for 24 months after the diagnosis or until death or the end of study observation (December 2014).
Study Cohort

Study Variables
The primary outcome for this study was the incidence of peripheral neuropathy, which was defined as a new ICD-9 diagnosis code indicating such (356. 4 indicator of the census-tract poverty level, marital status, and AJCC stage (extracted from SEER records). A modified Charlson comorbidity score was calculated with standard programming language made available by the SEER-Medicare program. 21 The receipt of chemotherapy was identified from claims data and was categorized into lines of therapy with the method described by Eaton et al. 22 First-line chemotherapy regimens were further categorized as to whether any agent received was neurotoxic (taxanes, platinum compounds, vinca alkaloids, bortezomib, oxaliplatin, and ixabepilone) 23 or nonneurotoxic (all others). The most prevalent individual neurotoxic agents (paclitaxel, carboplatin, and docetaxel) were assessed independently.
Statistical Methods
Statistical analyses were performed with the Statistical Analysis Systems software package (version 9.4; Statistical Analysis Systems, Cary, North Carolina), and cumulative incidence graphs were drawn with the R package cmprsk. 24 The incidence of CIPN, stratified by patient characteristics at diagnosis, was first summarized Cancer January 15, 2019 and then evaluated with chi-square tests for categorical variables (race/ethnicity, marital status, and AJCC stage) and with Mantel-Haenszel chi-square tests for ordinal variables (age group, census-tract poverty indicator, and Charlson comorbidity score).
We evaluated the time from the start of chemotherapy to the first Medicare claim associated with CIPN by plotting the cumulative incidence of CIPN, and we took into account the competing risk of death. Gray's test was used to compare chemotherapy types and ages at the time of diagnosis. Cox proportional hazards regression modeling was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for developing CIPN; variables significant in univariate analyses were included in a multivariate model (evaluated variables included age group, race/ethnicity, census-tract poverty indicator, marital status, AJCC stage, and Charlson comorbidity score). We tested the proportional hazards assumption for the Cox models by including an interaction term between the log of time and each variable in the final model, and the interaction terms were not significant.
RESULTS
Sample Description
A total of 11,149 female patients with breast cancer who received chemotherapy were included in this analysis (Fig. 1) 
Risk Factors for the Incidence of CIPN
Overall, 929 women (8.3%) had a CIPN claim within 1 year of starting chemotherapy. This proportion varied significantly by the age at breast cancer diagnosis, marital status, AJCC stage, and Charlson comorbidity score but not by race/ethnicity or census-tract poverty level (Table 1) . In this Medicare sample (≥66 years old), a relatively young age at the time of breast cancer diagnosis (P for trend < .0001), being married or the equivalent (HR, 1.30; 95% CI, 1.09-1.54), and the AJCC stage (HR for stage II, 1.34; 95% CI, 1.06-1.69; HR for stage III, 1.56; 95% CI, 1.23-1.98) were significant predictors of increased CIPN incidence (Table 2) . A sensitivity analysis, which removed patients with stage IV cancer, was completed, and the results did not appreciably change. Furthermore, a targeted analysis of diabetes as a potential risk factor independent of other comorbidities (Table 1) revealed no significant effect on CIPN.
Women treated with paclitaxel as part of their first-line treatment had the highest occurrence of CIPN (15.9%), whereas women treated with agents considered nonneurotoxic had the lowest incidence (5.0%; Fig. 2) ; increased risk emerged approximately 3 months after the start of first-line chemotherapy and increased throughout the 1-year follow-up period (Fig. 3) . After adjustments for covariates, paclitaxel was associated with a 2.7-fold greater risk for CIPN than nonneurotoxic regimens (HR, 2.69; 95% CI, 2.23-3.23; Table 2 ). In comparison with paclitaxel alone, we observed progressively lower CIPN incidence rates for carboplatin and paclitaxel, carboplatin and docetaxel, carboplatin alone, and docetaxel alone. The CIPN incidence for carboplatin administered alone or in combination with paclitaxel did not significantly differ from the CIPN incidence for paclitaxel alone. In contrast, the CIPN incidence for docetaxel administered alone or in combination with carboplatin was significantly lower than the CIPN incidence for paclitaxel alone but exceeded that for nonneurotoxic regimens (Fig. 2) .
DISCUSSION
To our knowledge, this is by far the largest claimbased study of CIPN incidence risk specific to patients with breast cancer. This retrospective study of SEERMedicare data from women diagnosed with AJCC stage II to IV breast cancer who did not have other cancers or preexisting claims for neuropathy found that paclitaxel as part of first-line treatment was associated with significantly higher CIPN incidence in comparison with other first-line chemotherapies. Two alternative neurotoxic therapies, carboplatin and docetaxel, alone and in combination with each other or paclitaxel, were associated with nonsignificantly elevated rates of developing CIPN in comparison with nonneurotoxic therapies. An increased risk of CIPN from paclitaxel emerged approximately 3 months after the start of first-line chemotherapy and escalated during the 1-year measurement interval.
These data are clinically important for highlighting the differential risk and time course of CIPN claims by type of chemotherapy agent(s). Prior research has largely relied on clinically assessed CIPN, which is heterogeneous in severity, and it may not always account for comorbid conditions or lifestyle factors that modulate the risk of CIPN. 25 Although the current study likely offers a more conservative estimate of CIPN (because of the greater severity required to obtain a claim), the primary goal was to estimate the differential risk of CIPN by chemotherapy agent, which should be independent of the Cancer January 15, 2019 overall level of CIPN in the breast cancer population. We also controlled for several comorbidities, which provide an unbiased estimate of the differential impact of chemotherapy regimens. Therefore, our findings can help oncologists and neurologists (to whom CIPN patients may be referred) to estimate the more severe spectrum of CIPN side-effect risk in the context of the type of chemotherapy administered.
Our findings are consistent with Hershman et al, 4 who analyzed Medicare-linked data from 1401 Southwest Oncology Group patients (aged 65 years or older) with mixed cancer diagnoses (including 175 patients with breast cancer) enrolled in 23 clinical trials; they found that paclitaxel led to 2-fold higher rates of grade 2 to 4 neuropathy than docetaxel, and this risk was amplified among patients receiving platinum therapy. Notably, they found older age, rather than younger age as in the current study, was associated with higher rates of neuropathy. However, with respect to our all-female breast cancer sample, the majority of the Hershman sample was male (72%) and had prostate cancer (46%); these differences could partly explain our different age-related findings. Our study also extends the comparison of neurotoxic regimens outside paclitaxel and docetaxel (see Fig. 2 for the listing of other agents). Comparative trials are expensive, and CIPN is a side effect (a safety signal), not a primary outcome; thus, studies have rarely compared chemotherapeutic regimens for relative propensities to cause CIPN. In one study of patients with breast cancer, 26 the incidence of grade 2 or higher sensory neuropathy Proportions (along with 95% confidence intervals) of women who developed CIPN by the type of neurotoxic agent given as part of first-line chemotherapy. If any agent given as part of first-line therapy was a platinum compound, oxaliplatin, vinca alkaloid, taxane, bortezomib, or ixabepilone, then the regimen was considered neurotoxic. The agents in the "other neurotoxic" regimen category (listed from most common to least common) were vinorelbine, cisplatin, oxaliplatin, vincristine, and bortezomib. Oxaliplatin is infrequently used as first-line chemotherapy for breast cancer (some literature suggests its offlabel use for metastatic breast cancer); similarly, bortezomib is primarily a myeloma agent (but has been infrequently studied in small-scale breast cancer trials). In this SEER-Medicare data set, both drugs occurred in less than 1% of cases as part of first-line therapy. CIPN indicates chemotherapy-induced peripheral neuropathy; SEER, Surveillance, Epidemiology, and End Results.
Cancer January 15, 2019 induced by paclitaxel worsened with the 12th course of cotreatment with bevacizumab in comparison with paclitaxel alone: 74% and 40%, respectively. In elderly patients with non-small cell lung cancer, a combination of either carboplatin or cisplatin with paclitaxel resulted in significantly more severe CIPN in the cisplatin arm.
27
As expected, the incidence rate of CIPN claims identified in this study was lower than other estimates of CIPN in the literature, which range from 10% to 80%.
1,2 An earlier SEER cohort study from 1991 to 2002 found an CIPN incidence density of 15.3 per 1000 person-years among 65,316 patients with breast cancer who received taxane-platinum combination therapy (a 3.3 times higher risk than the risk of patients who did not receive chemotherapy). 28 One potentially important reason for the discrepancy with prior estimates is that, in this SEER-Medicare claims database, patients with mild-grade CIPN may not have an ICD-9 diagnosis code listed. As noted previously, our data source is likely biased toward the detection of more severe neuropathy and may not capture the total incidence of CIPN. Thus, the conservative estimate from this study errs toward clinically relevant CIPN, but the approach probably underestimates less severe cases. In other words, claims data tend toward higher specificity but lower sensitivity for detecting all CIPN cases. The methodology used in our analysis, however, does not invalidate the comparisons of risk across the differing chemotherapy agents. A related issue concerns the estimation of CIPN base rates for nonneurotoxic regimens. Because we excluded cases with preexisting neuropathies (see Fig. 1 ) and we do not suspect systematic bias in the data set, we believe that it is appropriate to conclude that the 5% CIPN incidence rate is an accurate baseline estimate with this unique claims database.
One important implication from this research is that oncologists should routinely document CIPN in their clinical notes and code for CIPN severity because this may not be standard practice in the field. Attention to the onset and progression of CIPN as part of routine cancer care can have important implications for the patient. For instance, a recent analysis of 512 female survivors of cancer found that those who self-reported CIPN (47% of the sample) experienced significantly worse motor function (eg, slower gait), greater disability, and more falls than those who reported being asymptomatic; these relations were directly related to CIPN symptom severity. 5 Findings from this research also suggest that it would be valuable for oncologists to discuss with older patients with breast cancer the relative risks of CIPN for different chemotherapy regimens. Patients with vulnerabilities (eg, comorbid conditions) might, when informed about CIPN in the context of other treatment risks and benefits, opt to shift from a higher risk agent to lower risk one (ie, from paclitaxel to docetaxel) as part of first-line therapy; however, this suggestion has to be considered together with data on treatment efficacy. We recognize Cancer January 15, 2019 that each patient may weigh this information differently, but the current data offer a basis for such dialogue.
A further important contribution of the results from our study is the definition of risk factors associated with the time to incidence of CIPN claims. Few studies in the chemotherapy literature have carefully examined the time to event for neurotoxic sequelae. 29 Thus, the current findings offer new insight into the optimal period during which preventive measures can be applied to forestall the development of CIPN (eg, potentially co-administered with chemotherapy) and related health insurance claims/ costs and into identifying patients at greatest risk to prioritize such interventions. As noted earlier, there is an unmet need for adjunctive neuroprotective agents that exhibit effectiveness in preventing CIPN; our findings thus reinforce the importance of minimizing CIPN risks before first-line therapy.
The strengths of this study include a large and carefully selected sample of patients with breast cancer, stratification of risk factors, controlling for key covariates, a comparison of neurotoxic and nonneurotoxic therapies (rather than a comparison with no chemotherapy, which may overestimate incidence), and a focus on claims data. The limitations of this study include a retrospective analysis of a unique database (eg, older patients) with an incomplete set of covariates (eg, grading of CIPN, sensory neuropathy vs motor neuropathy vs autonomic neuropathy, chemotherapy dose/duration, obesity, and smoking status) and a lack of follow-up beyond 1 year (which may underestimate incidence), although we decided a priori to restrict our analysis to the incidence of CIPN within 1 year after the start of therapy for causal attribution. Also, we considered examining the effects of the number of treatment cycles, the early termination of chemotherapy due to emergent CIPN, and the use of adjunctive medication to treat CIPN; however, doing so would have been prohibitive because of the large variation in treatment regimens and a loss of statistical power. In clinical terms, women who develop more severe CIPN are likely to have fewer treatment cycles because of toxicity; yet, most available databases lack temporally precise indices that would support valid inferences regarding interrelations among these factors. Thus, prospective studies are needed to address these dynamic treatment/response patterns.
Prior studies with longer term assessments suggest the utility of implementing a prospective surveillance model to address risks in this population, 30 and such studies should include assessments at repeated intervals starting with treatment well into survivorship. 29 Future studies aimed at CIPN prophylaxis are potentially of greatest clinical value 17, 31 because it may be substantially harder to reverse CIPN once it has emerged.
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